Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Adamson

Showing results (301-310 of 342) with videos related to

Pageof 35
Sort By:
Cancer Research|February 12, 2005
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acidChunhui Di, Shaoxi Liao, David C Adamson, et al.
Anesthesia and Analgesia|March 23, 2006
Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstructionAthena F Zuppa, Susan C Nicolson, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report, Maryam Fouladi, Wayne L Furman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsElizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Intrathecal mafosfamide: a preclinical pharmacology and phase I trialSusan M Blaney, Frank M Balis, Stacey Berg, et al.
The Journal of Rheumatology|August 1, 1996
V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation studyL W Moreland, L W Heck, W J Koopman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group StudyNajat C Daw, Wayne L Furman, Clinton F Stewart, et al.
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group studyBrenda J Weigel, Susan M Blaney, Joel M Reid, et al.
The Lancet. Oncology|April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyYael P Mossé, Megan S Lim, Stephan D Voss, et al.
Pageof 35

Showing results (301-310 of 342) with videos related to

Sort By:
Pageof 35
Cancer Research|February 12, 2005
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acidChunhui Di, Shaoxi Liao, David C Adamson, et al.
Anesthesia and Analgesia|March 23, 2006
Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstructionAthena F Zuppa, Susan C Nicolson, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report, Maryam Fouladi, Wayne L Furman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsElizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Intrathecal mafosfamide: a preclinical pharmacology and phase I trialSusan M Blaney, Frank M Balis, Stacey Berg, et al.
The Journal of Rheumatology|August 1, 1996
V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation studyL W Moreland, L W Heck, W J Koopman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group StudyNajat C Daw, Wayne L Furman, Clinton F Stewart, et al.
Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group studyBrenda J Weigel, Susan M Blaney, Joel M Reid, et al.
The Lancet. Oncology|April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyYael P Mossé, Megan S Lim, Stephan D Voss, et al.
Pageof 35